David Weissman
Analyst · Tommy McJoynt with KBW. Please go ahead
Thank you, Claude. Good morning, everyone. Octave reported a net loss to shareholders of $6.9 million or $0.13 per share in the first quarter of 2026, compared to a net loss from continuing operations to shareholders of $16.1 million or $0.57 per share in the first quarter of 2025, an improvement of 57%. Consolidated EBITDA and adjusted EBITDA to shareholders increased to $3.6 million and $20.1 million, compared to a negative $5.5 million and negative $1.3 million, respectively, in the first quarter of 2025, representing a $9.1 million and $21.4 million improvement, respectively. Consolidated adjusted net income to shareholders was $16.6 million, or $0.37 per share, compared to a net loss of $6 million or $0.13 per share in the first quarter of 2025, an improvement of $22.6 million or $0.50 per share. Our non-GAAP metrics, adjusted EBITDA and adjusted net income, exclude the impact of a settlement of a potential litigation matter at Everspan, severance costs, other non-recurring costs, and equity compensation. The favorable movement in our results for the quarter were driven by an Insurance Distribution segment and lower corporate overhead. Total revenue for the insurance distribution segment grew 92% to $78.5 million in the first quarter of 2026. Drivers of this growth included the acquisition of ArmadaCare in the fourth quarter of 2025 and organic growth of 42%. ArmadaCare, while not included in our organic growth calculations, grew revenue organically by 10% compared to its first quarter of 2025. The diversity of our business and certain niche product lines helped deliver these favorable results in the face of softening conditions in certain lines. Insurance distribution net income to shareholders increased to $13.2 million in the quarter, compared to a net loss of $3.4 million in the prior year quarter, an improvement of $16.6 million. Insurance distribution adjusted EBITDA to shareholders grew nearly 4-fold to $25.3 million, compared to $7.1 million in the first quarter of 2025. And adjusted net income to shareholders was $22 million, compared to $2.5 million in the first quarter of 2025. That is an increase of nearly 8 times. Our insurance distribution results for the quarter were driven by a number of factors, including the October 2025 acquisition of ArmadaCare, organic growth across our diverse group of MGAs, higher profit commissions, lower interest expense, resulting from both a reduction of debt and lower financing costs. It's worthy to note that after a couple of years of negative growth, as I've discussed on prior calls, our exchange benefits platform in particular had a strong first quarter, posting record results in its core ESL business, a testament to the discipline and commitment of our team. The strong performance in the quarter, which on an absolute basis is also impacted by the seasonality of our A&H business, drove our margins to record highs 16.3% for pre-tax income to shareholders and 32.3% for adjusted EBITDA to shareholders, increasing 26 and 15 points respectively. As a result of seasonality and other factors such as the nature of de novos, we do anticipate variability in our results from quarter to quarter. Our results for the quarter also reflect our continued investment in de novo MGAs, which reduced EBITDA to shareholders by about $1.1 million in the first quarter of 2026 versus $600,000 in the first quarter of 2025. These costs were spread across approximately five MGAs. While not impacting our first quarter results, we ended the quarter by acquiring an additional 10% of Octave Ventures as well as additional stakes to 4 other MGAs, three of which related to Octave Ventures. The total cost of these NCI buy-ins was about $44 million. These were funded with cash and by the expansion of our existing term loan facility. Our insurance distribution business debt to EBITDA on a pro forma TTM basis was roughly 3.2 times at March 31, 2026. We believe our bank facilities are attractive from the standpoint that they have 5-year tenors, modest required amortization, and are currently at a spread of 275 basis points over SOFR, which declines based on leverage. As part of the increase, we agreed to provide the equity in Everspan's intermediate holding company as additional collateral, which is very much standard in bank-funded insurance financing transactions. Given that OSG guarantees the debt, this additional collateral also does not create a material change in the economic terms. Turning to Everspan, gross premiums written and net premiums written and earned in the quarter were $104 million, $32 million, and $20 million, up 19%, 80%, and 28% respectively, driven by the repositioning of our portfolio, which began late in 2024. First quarter production included the impact of 24 programs, four of which were new compared to last year and two of which were Octave-related programs. The actions we took, which I've previously spoken about, brought down our current quarter accident year loss ratio to 54%, while our active programs are running about a 57% loss ratio. Our reported net loss in the LAE ratio was 98.4% in the first quarter. As a result of losses and expenses incurred in connection with a settlement to resolve potential litigation matters related to an insurance claim. This settlement resulted in additional losses incurred of $2.1 million and LAE incurred for legal fees of $5.8 million. The settlement accounted for 39.6 loss ratio points in the quarter. On a pro forma basis, including the settlement costs, severance, as well as other expenses mostly related to timing differences, our combined ratio for the quarter was approximately 95%, which is more in line with our long-term expectations. For the first quarter of 2026, Everspan produced a pre-tax loss of $8 million and adjusted EBITDA was $2 million, up 2% from the first quarter of 2025. Our recent expense reduction initiatives at corporate also began to take hold in the first quarter of 2026 as well with nominal expenses declining to just over $12 million from $15 million last year. Moreover, adjusted expenses declined to $7.2 million from $10.6 million in the prior year comparable period. The difference between reported expenses and adjusted expenses in the current quarter were mainly attributable to acquisition and integration costs of about $1.1 million, severance and restructuring expenses of half a million, and equity compensation of $3.1 million, which included a catch-up accrual due to a change in performance factors of $1.7 million. We continue to evaluate all expenses in an effort to trend our adjusted expenses downward towards our longer-term goals. I will now turn the call back to Claude.